Glaxo’s Vaccines Chairman Moncef Slaoui to Retire Next Year

Updated on
  • Slaoui to leave board in March, remain as adviser until July
  • Debruyne to continue to run Glaxo’s vaccine business

GlaxoSmithKline Plc’s vaccines division chief, Moncef Slaoui, will retire next year after a nearly 30-year career at the U.K.’s biggest drugmaker.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.